header image

Page 46«..1020..45464748..6070..»

Brevard Zoo’s Bear ‘Brody’ Received Radiographs and Underwent First Round of Stem-Cell Therapy – SpaceCoastDaily.com

Two injections containing about five million stem cells delivered directly to Brodys hip jointsDuring last months surgery to address an issue with Brodys joints, Dr. Jeffrey Christiansen of Superior Veterinary Surgical Solutions collected a small amount of Brodys fat. (Brevard Zoo image)

BREVARD COUNTY MELBOURNE, FLORIDA During last months surgery to address an issue with Brodys joints, Dr. Jeffrey Christiansen of Superior Veterinary Surgical Solutions collected a small amount of Brodys fat.

A laboratory extracted stem cells from the fat sample, which can be used to reduce pain and inflammation and promote healing of the surgical site.

On Friday morning, Brody was brought back to the L3Harris Animal Care Center to receive his first dose of this medication.

Two injections containing about five million stem cells each were delivered directly to Brodys hip joints. To accomplish this, Dr. Christiansen carefully inserted a needle into Brodys hip and drew a small amount of joint fluid to confirm the tip was in the right place, then administered the injection.

A third, less-concentrated injection was delivered intravenously.

We also captured some radiographs to check on Brodys hip condition.

While we wont be able to evaluate the long-term effectiveness of the surgery for quite some time, he appears to be recovering without complication.

Brody woke from the anesthesia and was returned to his habitat. It is normal for animals to experience discomfort and lameness for a few days following stem-cell injections, but Brody is already back to being his normal, energetic self.

We have enough stem cells banked for an additional 15 doses, which will be administered throughout the course of Brodys life as needed.

Quality veterinary care is expensive. Click here to support animal wellness at the Zoo during this financially challenging time.

CLICK HERE FOR BREVARD COUNTY NEWS

Read the original post:
Brevard Zoo's Bear 'Brody' Received Radiographs and Underwent First Round of Stem-Cell Therapy - SpaceCoastDaily.com

Canine Stem Cell Therapy Market to Witness Stunning Growth to Generate Massive Revenue During Forecast 2020 2026 | VETSTEM BIOPHARMA, Cell Therapy…

Canine Stem Cell Therapy Market research is an intelligence report with meticulous efforts undertaken to study the right and valuable information. The data which has been looked upon is done considering both, the existing top players and the upcoming competitors. Business strategies of the key players and the new entering market industries are studied in detail. Well explained SWOT analysis, revenue share and contact information are shared in this report analysis.

The global Canine Stem Cell Therapy Market size is expected to Expand at Significant CAGR of +4% during forecast period (2020-2026).

The non-invasive stem cell obtaining procedure, augmented possibility of accomplishing high quality cells, and lower price of therapy coupled with high success rate of positive outcomes have collectively made allogeneic stem cell therapy a preference for veterinary physicians. Moreover, allogeneic stem cell therapy is 100% safe, which further supports its demand on a global level.

Get Sample Copy (Including FULL TOC, Graphs and Tables) of this report @:

https://www.a2zmarketresearch.com/sample?reportId=21262

Note In order to provide more accurate market forecast, all our reports will be updated before delivery by considering the impact of COVID-19.

Top Key Vendors of this Market are:

VETSTEM BIOPHARMA, Cell Therapy Sciences, Regeneus, Aratana Therapeutics, Medivet Biologics, Okyanos

Various factors are responsible for the markets growth trajectory, which are studied at length in the report. In addition, the report lists down the restraints that are posing threat to the global Canine Stem Cell Therapy market. It also gauges the bargaining power of suppliers and buyers, threat from new entrants and product substitute, and the degree of competition prevailing in the market. The influence of the latest government guidelines is also analyzed in detail in the report. It studies the Canine Stem Cell Therapy markets trajectory between forecast periods.

The report provides insights on the following pointers:

Market Penetration:Comprehensive information on the product portfolios of the top players in the Canine Stem Cell Therapy market.

Product Development/Innovation:Detailed insights on the upcoming technologies, R&D activities, and product launches in the market.

Competitive Assessment: In-depth assessment of the market strategies, geographic and business segments of the leading players in the market.

Market Development:Comprehensive information about emerging markets. This report analyzes the market for various segments across geographies.

Market Diversification:Exhaustive information about new products, untapped geographies, recent developments, and investments in the Canine Stem Cell Therapy market.

Get Up to 20% Discount on this Premium Report @:

https://www.a2zmarketresearch.com/discount?reportId=21262

The report summarized the high revenue that has been generated across locations like, North America, Japan, Europe, Asia, and India along with the facts and figures of Canine Stem Cell Therapy market. It focuses on the major points, which are necessary to make positive impacts on the market policies, international transactions, speculation, and supply demand in the global market.

Global Canine Stem Cell Therapy Market Segmentation:

Market Segmentation by Type:

Allogeneic Stem CellsAutologous Stem cells

Market Segmentation by Application:

Veterinary HospitalsVeterinary ClinicsVeterinary Research Institutes

Table of Contents

Global Canine Stem Cell Therapy Market Research Report 2020 2026

Chapter 1 Canine Stem Cell Therapy Market Overview

Chapter 2 Global Economic Impact on Industry

Chapter 3 Global Market Competition by Manufacturers

Chapter 4 Global Production, Revenue (Value) by Region

Chapter 5 Global Supply (Production), Consumption, Export, Import by Regions

Chapter 6 Global Production, Revenue (Value), Price Trend by Type

Chapter 7 Global Market Analysis by Application

Chapter 8 Manufacturing Cost Analysis

Chapter 9 Industrial Chain, Sourcing Strategy and Downstream Buyers

Chapter 10 Marketing Strategy Analysis, Distributors/Traders

Chapter 11 Market Effect Factors Analysis

Chapter 12 Global Canine Stem Cell Therapy Market Forecast

For more Information, Inquire @:

https://www.a2zmarketresearch.com/enquiry?reportId=21262

If you have any special requirements, please let us know and we will offer you the report as you want.

About A2Z Market Research:

The A2Z Market Research library provides syndication reports from market researchers around the world. Ready-to-buy syndication Market research studies will help you find the most relevant business intelligence.

Our Research Analyst Provides business insights and market research reports for large and small businesses.

The company helps clients build business policies and grow in that market area. A2Z Market Research is not only interested in industry reports dealing with telecommunications, healthcare, pharmaceuticals, financial services, energy, technology, real estate, logistics, F & B, media, etc. but also your company data, country profiles, trends, information and analysis on the sector of your interest.

Contact Us:

Roger Smith

1887 WHITNEY MESA DR HENDERSON, NV 89014

[emailprotected]

+1 775 237 4147

See the rest here:
Canine Stem Cell Therapy Market to Witness Stunning Growth to Generate Massive Revenue During Forecast 2020 2026 | VETSTEM BIOPHARMA, Cell Therapy...

Stem cells give hope for revival of Malaysia’s extinct rhinos – The Straits Times

KUANTAN, MALAYSIA (REUTERS) - Some skin, eggs and tissue samples are all that remain of Malaysia's last rhino, Iman, who died last November after years of failed breeding attempts.

Now scientists are pinning their hopes on experimental stem cell technology to bring back the Malaysian variant of the Sumatran rhinoceros, making use of cells from Iman and two other dead rhinos.

"I'm very confident," molecular biologist Muhammad Lokman Md Isa told Reuters in his laboratory at the International Islamic University of Malaysia. "If everything is functioning, works well and everybody supports us, it's not impossible."

The smallest among the world's rhinos, the Sumatran species was declared extinct in the wild in Malaysia in 2015.

Once it had roamed across Asia, but hunting and forest clearance reduced its numbers to just 80 in neighbouring Indonesia.

Iman, 25, died in a nature reserve on Borneo islandfollowing massive blood loss caused by uterine tumourswithin six months of the death of Malaysia's last male rhino, Tam.

Efforts to get the two to breed had not worked.

"He was the equivalent of a 70-year-old man, so of course you don't expect the sperm to be all that good," said Mr John Payne of the Borneo Rhino Alliance (Bora), who has campaigned for about four decades to save Malaysia's rhinos.

"It was obvious that, to increase the chances of success, one should get sperm and eggs from the rhinos in Indonesia. But right till today, Indonesia is still not keen on this."

Indonesia's environment ministry disputed accusations of cross-border rivalry as a reason why Malaysia's rhinos died out, saying talks continue on ways to work with conservationists in the neighbouring South-east Asian nation.

"Because this is part of diplomatic relations, the implementation must be in accordance with the regulation of each country," said MsIndra Exploitasia, the ministry's director for biodiversity conservation.

The Malaysian scientists plan to use cells from the dead rhinos to produce sperm and eggs that will yield test-tube babies to be implanted into a living animal or a closely related species, such as the horse.

The plan is similar to one for the African northern white rhinoceros, which numbers just two. Researchers in that effort reported some success in 2018 in producing embyronic stem cells for the southern white rhino.

But the process is still far from producing a whole new animal, say Dr Thomas Hildebrandt and Dr Cesare Galli, the scientists leading the research.

And even if it worked, the animals' lack of genetic diversity could pose a threat to long-term survival, Dr Galli told Reuters.

Indonesian scientist Arief Boediono is among those helping in Malaysia, hoping success will provide lessons to help his country's rhinos.

"It may take five, 10, 20 years, I don't know," Dr Arief added."But there has already been some success involving lab rats in Japan, so that means there is a chance."

Japanese researchers have grown teeth and organs such as pancreas and kidneys using embryonic stem cells from rats and mice in efforts to grow replacement human organs.

For now, however, Iman's hide will be stuffed and put on display alongside Tam's in a Borneo museum.

Read the rest here:
Stem cells give hope for revival of Malaysia's extinct rhinos - The Straits Times

‘Integrity, professionalism and empathy, the ethos of officering’ – The Island.lk

(The seventh death anniversary of Deshamanya Gen. Dennis Perera fell on 11 August. This is the Dennis Perera memorial oration 2016 delivered by Air Chief Marshal Gagan Bulathsinghala RWP, RSP, VSV, USP, Mphil, Msc, FIM(SL)ndc, psc, Former Commander of the Air Force and Ambassador to Afghanistan)

The former US President and Supreme Commander Allied Expeditionary Forces in WW 2, Gen. Dwight D. Eisenhower states:

The supreme quality for leadership is unquestionable INTEGRITY.

Without it, no real success is possible;

No matter whether it is on a section, gang, a football field,

In an army or in an office!

Reflecting on the illustrious career of the late Deshamanya Gen. Dennis Perera, one sees an outstanding leader whose lifetime principle was integrity of the highest order personifying exemplary moral courage to do what is needed and what is right, while being an officer and gentleman, par-excellence.

The young Master Dennis Perera was educated at St. Peters College, Colombo, and excelled as a multifaceted student both in academics and sport. In 1949, at the age of 19, he answered the call to the profession of arms to join the then young Ceylon Army.

Young Master Dennis Pereras mothers dream was for her son to a join the order and become a Priest, due to her strong faith in religion. However, an uncle of Master Perera, who was in the Ceylon Police, saw him more as soldier material and convinced his parents to let him join the Ceylon Army.

General Perera received his initial military training at Mons Officer Cadet School, UK, and the Royal Military Academy Sandhurst. He was also a graduate of the British Armys Staff College, Camberley. In 1977, at the age of 46, he was bestowed the twin honours of being the first Engineer officer and also the youngest officer ever to be made the Commander of the Sri Lanka Army. Further the late Gen Perera was an alumni of the prestigious National Defence Collage of India.

On retirement, Gen. Perera continued to serve the nation and the corporate sector, first as the High Commissioner to Australia, and later as Chairman of the Securities Exchange Commission, and as Chairman of Ceylon Tobacco Company, and two other high performing Companies. In the year 2000, acknowledging his meritorious service to the nation he was bestowed the title, Deshamanya. He was next elevated to a Four Star General, in the year 2000.

Gen. Perera possessed a unique character and was known for his compassion and inspiration towards the people around him. He was well known to be a shrewd strategist and a sound leader who always lived up to the motto of the Royal Military Academy Sandhurst, Serve to Lead. Gen Perera maintained the highest level of integrity as an Officer and remains a role model for officering in the armed forces of Sri Lanka. As an officer, and a statesman, he made an everlasting impression for the military fraternity and the nation.

In 2010, I had an interesting experience when I flew with Gen. Perera and his gracious Lady to attend the golden Jubilee celebrations of the National Defence College, New Delhi. Though he had hung up his uniform, some time back, I felt the he remained a hard core General, the way he expressed his thoughts on military traditions. Every conversation, I had with Gen. Perera, made me feel proud as a military officer. It was very apparent that he was most upright and proud of the profession of arms. He professed that a military officer should never lean against any one or be a shadow to any one, and must stand up firm for what is right.

I am very confident that this august audience needs no elaboration on Gen. Pereras role in establishing the KDU. Gen. Perera pioneered and triggered the conversion of the Kandawala Estate into the esteemed Military University it is today.

It was indeed fitting that Gen. Perera himself was appointed the first Chancellor after it became a University. Gen. Dennis Pereras visionary leadership and foresight provided our Army with the Commandos and the Womens Corps as integral units, in corporate parlance two timely investments that have brought rich dividends.

The Association of Retired Flag Rank Officers (ARFRO), which has brought us together this evening, was another successful effort of Gen Dennis Perera. This is the professional institution of the profession of arms in Sri Lanka. It is a member of the esteemed Organization of Professional Associations of Sri Lanka and is affiliation to the World Consultative Association of Retired Generals, Admirals & Air Marshals. A truly worthy outfit to be in, for military veteran of Flag rank after a retirement.

Ladies and gentlemen, Gen. Dennis Perera, was a passionate leader, a visionary and a professional, whose life is worthy of celebration at the highest level of esteem and appreciation.

Considering the epitome of military officering in Sri Lanka whom this oration is dedicated to, I chose as my discourse the obvious attributes practiced by him.

General Collin Powell, the former US Secretary of State said:

The most important thing I learned is that soldiers watch what their leaders do. You can give them classes and lecture them forever, but it is your personal example they will follow.

Ladies and gentlemen, from the very beginning of civilization, when mankind engaged in war fighting, the officer was the nucleus and the pivot around which the rank and file rallied for guidance, direction and leadership. Thus, an officer with firm, coherent decisional ability and robust leadership becomes important for the structural integrity of any military unit.

The contemporary armed forces are ramping up their efforts to groom a capable breed of officers to lead and confront the asymmetric threats encountered by nations in battle spaces which are not clearly defined. It is the need of the day that this effort should persist from the moment an officer joins, as it is only knowledge and its continuous application that will make one perfect.

In this context I would like to quote from Aristotle

We are what we repeatedly do; Excellence, therefore, is not an act but a habit.

For any military officer, Integrity is the primary attribute which strengthens his moral fiber to control emotions, both in times of adversity and success. Integrity is a leadership attribute discussed at length in our profession.

Integrity is defined as, The quality of truthfulness, honesty and maintaining of moral standard.

Integrity then should not be considered a mere attribute, but a virtue to live by for any officer.

The world today discusses and studiously studies Ethics in all spheres public, corporate, national and international. Similarly the military today has been rediscovered around an ethical compass, thus military leaders need to be aware of the dramatic lift in the bar of standards in accountability, honesty, and trust.

An officer is entrusted with; state secrets relating integrity of a nation and the lives of the public and the men he leads. If an officer is found to be dishonest or disloyal, it means that his character has two sides and one will manifest to suit the circumstance, to meet his personal liking and not the common goal.

The officers as leaders must demonstrate the moral fiber to be selfless to address the needs of their subordinates before their own, and possess the integrity to seek wholesome solutions.

Our great nation expects complete honesty and integrity from us; upon which it has entrusted its security and integrity and given us all which have said we needed to do the job. Anything less, if delivered will ultimately put our nation at risk by sabotaging its future, and its strategy to compete in the world. Therefore General Eisenhowers edict that Integrity is the supreme quality of leadership is underscored with no doubt.

Even though midway, I need to make a disclaimer that I will generalize in relation to gender and refer to military personnel as HE or HIM, only to make life easier for me in this discourse and in no way lessen the immense contribution of the ladies in our profession. Professionalism is the next attribute of officering that I endeavor to relate to.

General Charles De Gaulle (Galle), the decorated French Soldier and President describes the men of our profession as:

Men who adopt the profession of arms submit to their own free will to a law of perpetual constraint of their own accord.

If they drop in their tracks, if their ashes are scattered in the four winds that is all part and parcel of their job.

The contemporary military culture is far distanced from the traditional forms of war fighting, as cyber space, smart equipment and proactive tactics have encroached at a rapid pace.

However, technology cannot and will not replace the concept of professional officering. Thus the military needs a corps of highly skilled technology savvy officers to command them in tomorrows uncertain environment.

On the other hand, the knowledge of common affairs and skill that is expected from an officer cannot be obtained only by referring to a stack of books and manuals only. It is cumulative, and gained through hard experiences learnt through failures and the continuous attempts to succeed.

The men, the officer of today is called upon to command, are technology savvy, well educated, well socialized and have grown up in a free thinking environment. To be able command their respect and followership one needs to prove professional ability beyond doubt.

The opponents of peace the officer of today will be called upon to confront, are shrewd exponents of asymmetric warfare and are capable of exceptional cruelty and violence as well as, well strategized operations. They have learned and trained to exploit technology and the human mind, with much precision and process to achieve their sick ideological objectives.

Their standard modus operandi is to attack the social fabric at the same time from many directions.

In this context it is imperative for the officer who leads from the front to develop knowledge and all round capacity that includes outside ones lane knowledge.

Ladies and gentlemen, at the end of the day, the most important and cardinal characteristic a professional needs to have is the knowledge and competence in ones own field.

The legendary Field Marshal Sam Manekshaw, of the Indian army has once said:

.. you cannot be born with professional knowledge and professional competence even if you are a child of Prime Minister, or the son of an industrialist or the progeny of a Field Marshal. Professional knowledge and professional competence have to be acquired by hard work and constant study.

In addition to the explicit and tacit knowledge an officer is armed with, he also needs to have an inner thirst and passion for knowledge for things unknown and things outside the zone of comfort. For this the officer needs to be enthusiastic in the never ending process of developing new skills and acquiring new knowledge.

Due to the uncertainty, the high stress levels, and the continuously evolving threats to the society he serves, an officers professional competence must be at the highest level at all times.

For this it is necessary, that the appropriate candidates only be selected to hold the commission, and the aspects of their selection, training, assigning and evaluation, given the highest precedence of priority by the authorities concerned. Incompetent and unprofessional officers, who are unsuitable to lead men and incapable of rational decision-making, should not be tolerated in any military institution.

The popular edict goes on to say that there are no bad soldiers but only bad officers

Professionalism for an officer is not only knowing the job, but it also relates to the discipline and decorum that he and his men maintain while engaged on the task, whatever the circumstances may be. This goes beyond an officer inspecting haircuts, and turn out and bearing but reaches out to greater depth of intervening into unprofessional conduct, such as human rights abuses, or even fraternization. Both these occur due to the lack of self-control and the moral fiber to control ones emotions and is a failure that should be purged from the professional officer corps at the first hint of existence.

In this context, it is the conduct of the officer that the men will follow, and this will then decide, the esteem of the unit in the social domain it operates.

As per the Sri Lanka Air Force Ethos, Core Values and Standards adopted from the Royal Air Force, it applies the following test to determine the code of social conduct.

Have the actions or behaviour of an individual adversely impacted, or are they likely to impact, on the efficiency or operational effectiveness of the Sri Lanka Air Force?

This test applies to all individuals of the SLAF, on or off duty, in order to undermine unprofessional behaviour without hesitation. As far as the social fabric surrounding the Sri Lankan military is concerned.

I strongly believe that this self-query can be applied to any service institution. In the Sri Lankan post conflict environment, where we experience numerous cynical and false expressions, relating to our past and present conduct, it is the leadership that must emerge with professionalism. For this the cornerstone of professionalism must be invented upon good order, discipline, decorum, and exemplary conduct. If our profession loses the trust and confidence of the societal domain, due to unprofessional conduct, it becomes increasingly difficult to acquire the much needed popular support for the conduct of our core competency. Therefore, we must bear in mind that we as officers are responsible for the publics perception of our institutions.

From professionalism I now delve into Empathy, the softer and lesser discussed attribute in an officers repertoire.

General Omar Bradley better known as the soldiers general during WW2 in one of his papers on Leadership states;

A leader should possess human understanding and consideration for others. Men are not robots and should not be treated as though they were machines. I do not by any means suggest coddling. But men are highly intelligent, complicated beings who will respond favourably to human understanding and consideration. By this means, their leader will get maximum effort from each of them.

Knowing your men and to possess the ability to understand and share their feelings are essential empathetic traits of a leader. It is important to develop a memory for names and faces of the people under ones command. The saying goes, a mans name is to him the most important word in his language. Our subordinates endure great pains emotionally, psychologically, physically and socially during war and during peace.

For an officer to mitigate the emotional pain, the officer needs to be able to empathize and make the man feel that his pain is felt even though not necessarily shared or the issue resolved. The approach to resolving subordinates emotional issues is often confounding as only the manifestation is seen.

Human and social issues faced by our subordinates cannot be resolved by the mere application of military law or generous distribution of welfare items to families of subordinates. The genuine caring nature and the ability to feel subordinates pain and see their point of view even though not necessarily accepted are the qualities of an empathetic leader.

Thus, empathy, is an integral part of officering as our subordinates, are constantly exposed to multifarious and intense stressors.

If we carefully review history we see the empathetic side of leaders who were ruthless in the execution of war.

Field Marshall Erwin Rommell the legendry Dessert Fox of the Africa Korps, is known to have been greatly loved by his men and respected by the enemy; he is said to have looked after his men well and grieved at their loss, It is also said that he ignored orders from Nazi leadership to summarily execute prisoners of war.

When an officer is aware of the emotional state of his men, it creates an unspoken bond of trust between them and the officer. Without empathy and compassion ones subordinates will always keep their guards up and be cautious and will have less camaraderie towards their leader.

General George S. Patton, better known by men as ole blood an guts is quoted in the book War as I knew it

Officers are responsible, not only for the conduct of their men in battle, but also for their health and contentment when not fighting. An officer must be the last man to take shelter from fire, and the first to move forward.

Throughout my discourse I have elaborated on three core attributes that are the Ethos of Officering, Integrity, Professionalism, and Empathy. The thresholds of these three attributes converge in most instances supporting one and other.

These three attributes taken in broader sense encompass all values that we would like a leader of our choice to possess. It is not rationally possible for a single human being to possess all three values in their entirety, but we as seniors need to emphasize the importance of these attributes to our younger generations.

As I said, our younger generations have grown up in a free thinking environment and tend to refer to the words realism and pragmatism instead of values. It is in this sense that we need to create awareness of the importance of means as well as the successful achievement of the end It is here that the Ethos of officering comes into bearing.

In the SLAF we have recently introduced the booklet ETHOS & CORE VALUES in this we have translated our values into a broad statement.Through this statement our intention is to give the officer an identity based on value and say this is who I am. At this point I must acknowledge that this book is based on an inheritance from The Royal Air Force but has been remodeled to suit our needs, our culture, and our own values.

The art of officering has evolved in many ways to suit the trends of change, but there are many unwritten laws, traditions, customs, and a value based system of officering handed down by our forefathers of this profession that our generation will now hand over to the next. Men and technology will come and retire but these value based traditions cannot be changed nor should review be attempted, as they stem from valuable lessons learnt from engagement in painful conflict.

Integrity, professionalism and empathy are the attributes that serve as the pillars of genuine officering, they need to be taught, nurtured, developed and appreciated when practiced. This will ensure that the respect and esteem of our sacred profession will remain intact.

May the Late Deshamanya Gen. Dennis Perera be remembered by the future generation for his excellence in soldiering!

More:
'Integrity, professionalism and empathy, the ethos of officering' - The Island.lk

Health and Fitness: Hip replacement surgery: getting back to what you love – taosnews

More than 300,000 total hip replacement surgeries are performed annually in the United States.

Awhile back, I helped develop a hiking plan for a friend who had hip replacement surgery and wanted to return to hiking gradually as part of her physical therapy. It didn't occur to me that I would need the same type of plan one day.

I have had the opportunity to hike many of the beautiful trails near Taos over the last 30 years. I began to write about hiking for the Taos News in 2011 and wrote the "Taos Hiking Guide" in 2015.

Up until about two years ago, I was hiking 14 miles round trip to places like Las Trampas Lakes near the Truchas Peaks, sometimes backpacking with no problem and little pain. Then that winter, I started to experience a lot of discomfort in my right hip and leg; occasionally my leg would just collapse and refuse to work.

I had seen Dr. Keith Christian, DOM, of Taos Chiropractic Health Center over time whenever I had a little twinge of pain in my knee or hip and for awhile, he was able to straighten out my body and reduce the pain.

But there came a time when no amount of adjusting reduced the pain or improved function. We both realized that something new was going on and Christian suggested that there was some significant deterioration in my hips.

When I got an X-ray at Holy Cross Hospital last summer, it showed that I had worn out all the cartilage in my right hip and had only a bit remaining in my left hip. I made an appointment with Dr. Sean Marvil at Taos Orthopaedic Institute to talk about options for treatment.

It turns out there aren't many options: steroid shots can help with pain for a period of months and stem cell therapy is an emerging approach that has promise for the future, but the proposed solution from Marvil was hip replacement surgery, technically known as total hip arthroplasty, at least for my right hip.

The number of hip replacement surgeries in the U.S. is projected to grow over time. The average age for hip replacement is 67 years old, according to the American Joint Replacement Registry. In addition to improving the quality of life for patients, one study in Sweden showed that hip replacement surgery also may add years to a person's life.

According to the two surgeons I consulted, the reason I needed the procedure is osteoarthritis: a condition that damages the cartilage covering the end of the bones where they come together in the hip socket. This condition arises from a combination of wear and tear and genetics.

Although hip surgery is generally classified as elective surgery, doctors may recommend it if the condition is causing a lot of pain and interfering with the ability to do basic tasks like getting dressed and walking.

Although I had two other friends who have had hip replacement surgery and I was beginning to wonder if my pain was the result of arthritis l, I was still surprised and a little angry at the diagnosis. I had somehow assumed that being active and fit would protect me from needing this kind of surgery. And I am younger than the average age for the surgery by a number of years.

After I had a chance to reflect on the situation a bit, I was relieved that at least there was something that could be done about the pain and dysfunction and that I could again be hiking longer distances. I made the decision to have the surgery and planned for it sometime in the spring of 2020.

Then life intervened. With the coming of the COVID-19 virus, elective surgeries were delayed. My mom who had been diagnosed with ovarian cancer at Christmas passed away in April and during that time all my priorities changed.

Finally in early June, I was able to see a surgeon in Colorado. Due to the requirements of my insurance plan, I had to have the procedure done in Colorado from a preapproved list of doctors in order to have it covered. This was a difficult decision, as I would have been happy to work with Marvil at Taos Orthopaedic Institute.

After reading reviews of all the approved physicians, I chose Dr. Joseph Assini at OrthoOne at Swedish Medical Center in Denver, due to his favorable reviews by past patients.

When asked about the benefits of hip replacement surgery, Assini said, "It is always great to see the amazing pain relief patients get after a total hip replacement. While the path for each patient is variable in terms of time and discomfort, patients will end up happy and generally back to most activities six to 12 weeks from surgery. Being able to help patients get back their quality of life is very rewarding."

Before the surgery in June, I had a variety of exams and tests, including a screening for the COVID virus. All the test results looked good.

Early on the morning of June 24, my sister Brenda Staab picked me up and we went across town to the Rocky Mountain Surgery Center. I had spoken to the anesthesiologist the night before, who advised I have no food for eight hours and no liquids four hours before.

When I arrived, I checked in and was taken back to the preoperative area where an IV was started and I was given some painkillers. Assini stopped by and marked the right hip where the incision would be.

The anesthesiologist discussed the options with me. The two primary options were general anesthetic or a spinal block with additional medication that made sure the patient was asleep for the operation. We agreed on the spinal block as it is less impactful to the body and less likely to cause nausea and other side effects. He explained that he would put some cold gel on my back before giving me the injection. The cold gel was the last thing I remember until waking up a short time later.

What was amazing to me was that the actual hip replacement took under an hour. After demonstrating I could walk with crutches and perform certain other bodily functions to ensure that the spinal block had worn off, I was able to go home later the same day as the procedure.

I came back home to Taos the Sunday after my surgery to settle into the recovery process.

Recovery and physical therapy

Right after the surgery, I had nausea and a fair amount of pain. I was surprised by the extent of the swelling and bruising I experienced, not only in my hip, but also all the way down my leg to my foot, although Assini and staff reassured me that what I was experiencing was in the normal range.

For the first two weeks after surgery, I had to wear compression stockings which were hot and uncomfortable, but reduced the risk of a blood clot, one of the major risks of surgery. I've been taking two aspirin per day as a blood thinner to prevent clots and will need to continue to do so for a total of six weeks.

The pain medication that was prescribed to me was oxycodone - a narcotic drug with many side effects. It carries with it the risk of addiction. For the first few days, I took it every four to six hours and found it made me lightheaded and added to my nausea. Since then, I have been taking only one per day to help me sleep at night and am ready to begin to end that use as well.

In order to get back into shape for hiking and gardening, I have had the pleasure of working with Amryn Ayres of Physical Therapy and Rehab, a program of Holy Cross Hospital. Ayres received her doctorate in physical therapy just over two years ago and has worked at Physical Therapy and Rehab since the beginning of April.

She said, "The goal for physical therapy is to get people back to what they love. Surgery in general has widespread effects on the body in regard to motion, strength and overall function. As physical therapists, we are trained to identify specific impairments and guide you back to feeling better and living your life."

I first saw Ayres five days after surgery. She assessed my mobility and put together a series of exercises for me to do at home. She's also looked at my incision and helped determine it was ready to have the stitches removed.

I have been going to physical therapy one to two times a week since returning home and can feel that my hip and leg are becoming stronger.

After hip replacement on the right side, the patient is not able to drive for several weeks. I found Michelle Chandler, who in addition to being a musician and executive director of the Taos Youth Music School, offers various services to individuals and couples, including ministerial counseling and practical support. Chandler took me to physical therapy and also grocery shopping. Without her assistance, I would not have been able to navigate the first few weeks after surgery.

Also, 10,000 Wags Pet Resort was helpful. They picked up my dog twice a week and took him to play group so he got some exercise when I couldn't walk him.

Although I am not done recovering, I can feel that I'm stronger every day and have been returning to some of my regular activities slowly. I was cleared to drive at about four weeks after surgery and am slowly returning to short hikes with my dog, while continuing my physical therapy appointments and exercises at home.

At five weeks after surgery, I have much better mobility in my hip and the remaining muscle pain from the surgery is gradually decreasing.

Not surprisingly, another thing I observed is having medical insurance is important. The total bill covered by insurance was more than $73,000, with my portion totaling around $3,000.

I may need to have my left hip replaced at some point. But for now, I am going to focus on healing and becoming stronger, so that by the time fall is here, I will be once again hiking high in the mountains around Taos watching the leaves turn to gold.

Excerpt from:
Health and Fitness: Hip replacement surgery: getting back to what you love - taosnews

Global Canine Stem Cell Therapy Market 2027 Register a Xx% CAGR In Terms Of Revenue: VETSTEM BIOPHARMA, Cell Therapy Sciences, Regeneus, Aratana…

Canine Stem Cell Therapy Market

DataIntelo, 12-08-2020: The research report on the Canine Stem Cell Therapy Market is a deep analysis of the market. This is a latest report, covering the current COVID-19 impact on the market. The pandemic of Coronavirus (COVID-19) has affected every aspect of life globally. This has brought along several changes in market conditions. The rapidly changing market scenario and initial and future assessment of the impact is covered in the report. Experts have studied the historical data and compared it with the changing market situations. The report covers all the necessary information required by new entrants as well as the existing players to gain deeper insight.

Furthermore, the statistical survey in the report focuses on product specifications, costs, production capacities, marketing channels, and market players. Upstream raw materials, downstream demand analysis, and a list of end-user industries have been studied systematically, along with the suppliers in this market. The product flow and distribution channel have also been presented in this research report.

Get a PDF Copy of the Sample Report for Free @ https://dataintelo.com/request-sample/?reportId=82309

The Major Manufacturers Covered in this Report:VETSTEM BIOPHARMACell Therapy SciencesRegeneusAratana TherapeuticsMedivet BiologicsOkyanosVetbiologicsVetMatrixMagellan Stem CellsANIMAL CELL THERAPIESStemcellvet

The Research Study Focuses on:

By Types:Allogeneic Stem CellsAutologous Stem cells

By Applications:Veterinary HospitalsVeterinary ClinicsVeterinary Research Institutes

By Regions:

To get this report at incredible Discounts, visit @ https://dataintelo.com/ask-for-discount/?reportId=82309

The Canine Stem Cell Therapy Market Report Consists of the Following Points:

Make an Inquiry of the Canine Stem Cell Therapy Market Report @ https://dataintelo.com/enquiry-before-buying/?reportId=82309

In conclusion, the Canine Stem Cell Therapy Market report is a reliable source for accessing the research data that is projected to exponentially accelerate your business. The report provides information such as economic scenarios, benefits, limits, trends, market growth rate, and figures. SWOT analysis is also incorporated in the report along with speculation attainability investigation and venture return investigation.

About DataIntelo:DATAINTELO has set its benchmark in the market research industry by providing syndicated and customized research report to the clients. The database of the company is updated on a daily basis to prompt the clients with the latest trends and in-depth analysis of the industry. Our pool of database contains various industry verticals that include: IT & Telecom, Food Beverage, Automotive, Healthcare, Chemicals and Energy, Consumer foods, Food and beverages, and many more. Each and every report goes through the proper research methodology, validated from the professionals and analysts to ensure the eminent quality reports.

Contact Info:Name: Alex MathewsAddress: 500 East E Street, Ontario,CA 91764, United States.Phone No: USA: +1 909 545 6473 | IND: +91-7000061386Email: [emailprotected]Website: https://dataintelo.com

Here is the original post:
Global Canine Stem Cell Therapy Market 2027 Register a Xx% CAGR In Terms Of Revenue: VETSTEM BIOPHARMA, Cell Therapy Sciences, Regeneus, Aratana...

Coronavirus Drug and Treatment Tracker – The New York Times

The Covid-19 pandemic is one of the greatest challenges modern medicine has ever faced. Doctors and scientists are scrambling to find treatments and drugs that can save the lives of infected people and perhaps even prevent them from getting sick in the first place.

Below is an updated list of 20 of the most-talked-about treatments for the coronavirus. While some are accumulating evidence that theyre effective, most are still at early stages of research. We also included a warning about a few that are just bunk.

We are following 20 coronavirus treatments for effectiveness and safety:

Tentative or

mixed evidence

We are following 20 coronavirus treatments

for effectiveness and safety:

Tentative or

mixed evidence

We are following 20 coronavirus treatments

for effectiveness and safety:

There is no cure yet for Covid-19. And even the most promising treatments to date only help certain groups of patients and await validation from further trials. The F.D.A. has not fully licensed any treatment specifically for the coronavirus. Although it has granted emergency use authorization to some treatments, their effectiveness against Covid-19 has yet to be demonstrated in large-scale, randomized clinical trials.

This list provides a snapshot of the latest research on the coronavirus, but does not constitute medical endorsements. Always consult your doctor about treatments for Covid-19.

New additions and recent updates:

Added ivermectin, a drug typically used against parasitic worms that is being increasingly prescribed in Latin America. Aug. 10

Updated descriptions for several treatments. Aug. 10

We will update and expand the list as new evidence emerges. For details on evaluating treatments, see the N.I.H. Covid-19 Treatment Guidelines. For the current status of vaccine development, see our Coronavirus Vaccine Tracker.

WIDELY USED: These treatments have been used widely by doctors and nurses to treat patients hospitalized for diseases that affect the respiratory system, including Covid-19.

PROMISING EVIDENCE: Early evidence from studies on patients suggests effectiveness, but more research is needed. This category includes treatments that have shown improvements in morbidity, mortality and recovery in at least one randomized controlled trial, in which some people get a treatment and others get a placebo.

TENTATIVE OR MIXED EVIDENCE: Some treatments show promising results in cells or animals, which need to be confirmed in people. Others have yielded encouraging results in retrospective studies in humans, which look at existing datasets rather than starting a new trial. Some treatments have produced different results in different experiments, raising the need for larger, more rigorously designed studies to clear up the confusion.

NOT PROMISING: Early evidence suggests that these treatments do not work.

PSEUDOSCIENCE OR FRAUD: These are not treatments that researchers have ever considered using for Covid-19. Experts have warned against trying them, because they do not help against the disease and can instead be dangerous. Some people have even been arrested for their false promises of a Covid-19 cure.

EVIDENCE IN CELLS, ANIMALS or HUMANS: These labels indicate where the evidence for a treatment comes from. Researchers often start out with experiments on cells and then move onto animals. Many of those animal experiments often fail; if they dont, researchers may consider moving on to research on humans, such as retrospective studies or randomized clinical trials. In some cases, scientists are testing out treatments that were developed for other diseases, allowing them to move directly to human trials for Covid-19.

All treatmentsWidely usedPromisingTentative or mixedNot promisingPseudoscience

Antivirals can stop viruses such as H.I.V. and hepatitis C from hijacking our cells. Scientists are searching for antivirals that work against the new coronavirus.

PROMISING EVIDENCE EVIDENCE IN CELLS, ANIMALS AND HUMANSEMERGENCY USE AUTHORIZATIONRemdesivirRemdesivir, made by Gilead Sciences, was the first drug to get emergency authorization from the F.D.A. for use on Covid-19. It stops viruses from replicating by inserting itself into new viral genes. Remdesivir was originally tested as an antiviral against Ebola and Hepatitis C, only to deliver lackluster results. But preliminary data from trials that began this spring suggested the drug can reduce the recovery time of people hospitalized with Covid-19 from 15 to 11 days. (The study defined recovery as either discharge from the hospital or hospitalization for infection-control purposes only.) These early results did not show any effect on mortality, though retrospective data released in July hints that the drug might reduce death rates among those who are very ill.

TENTATIVE OR MIXED EVIDENCE EVIDENCE IN CELLS, ANIMALS AND HUMANSFavipiravirOriginally designed to beat back influenza, favipiravir blocks a viruss ability to copy its genetic material. A small study in March indicated the drug might help purge the coronavirus from the airway, but results from larger, well-designed clinical trials are still pending.

TENTATIVE OR MIXED EVIDENCE EVIDENCE IN CELLS, ANIMALS AND HUMANSMK-4482Another antiviral originally designed to fight the flu, MK-4482 (previously known as EIDD-2801) has had promising results against the new coronavirus in studies in cells and on animals. Merck, which has been running clinical trials on the drug this summer, has announced it will launch a large Phase III trial in September.Updated Aug. 6

TENTATIVE OR MIXED EVIDENCE EVIDENCE IN CELLS Recombinant ACE-2To enter cells, the coronavirus must first unlock them a feat it accomplishes by latching onto a human protein called ACE-2. Scientists have created artificial ACE-2 proteins which might be able to act as decoys, luring the coronavirus away from vulnerable cells. Recombinant ACE-2 proteins have shown promising results in experiments on cells, but not yet in animals or people.

TENTATIVE OR MIXED EVIDENCE EVIDENCE IN CELLS AND HUMANS IvermectinFor decades, ivermectin has served as a potent drug to treat parasitic worms. Doctors use it against river blindness and other diseases, while veterinarians give dogs a different formulation to cure heartworm. Studies on cells have suggested ivermectin might also kill viruses. But scientists have yet to find evidence in animal studies or human trials that it can treat viral diseases. As a result, Ivermectin is not approved to use as an antiviral.

In April, Australian researchers reported that the drug blocked coronaviruses in cell cultures, but they used a dosage that was so high it might have dangerous side effects in people. The FDA immediately issued a warning against taking pet medications to treat or prevent Covid-19. These animal drugs can cause serious harm in people, the agency warned.

Since then a number of clinical trials have been launched to see if a safe dose of ivermectin can fight Covid-19. In Singapore, for example, the National University Hospital is running a 5,000-person trial to see if it can prevent people from getting infected. As of now, theres no firm evidence that it works. Nevertheless ivermectin is being prescribed increasingly often in Latin America, much to the distress of disease experts.Updated Aug. 10

NOT PROMISING EVIDENCE IN CELLS AND HUMANS Lopinavir and ritonavirTwenty years ago, the F.D.A. approved this combination of drugs to treat H.I.V. Recently, researchers tried them out on the new coronavirus and found that they stopped the virus from replicating. But clinical trials in patients proved disappointing. In early July, the World Health Organization suspended trials on patients hospitalized for Covid-19. They didnt rule out studies to see if the drugs could help patients not sick enough to be hospitalized, or to prevent people exposed to the new coronavirus from falling ill. The drug could also still have a role to play in certain combination treatments.

NOT PROMISING EVIDENCE IN CELLS, ANIMALS AND HUMANSHydroxychloroquine and chloroquineGerman chemists synthesized chloroquine in the 1930s as a drug against malaria. A less toxic version, called hydroxychloroquine, was invented in 1946, and later was approved for other diseases such as lupus and rheumatoid arthritis. At the start of the Covid-19 pandemic, researchers discovered that both drugs could stop the coronavirus from replicating in cells.

Since then, theyve had a tumultuous ride. A few small studies on patients offered some hope that hydroxychloroquine could treat Covid-19. The World Health Organization launched a randomized clinical trial in March to see if it was indeed safe and effective for Covid-19, as did Novartis and a number of universities. Meanwhile, President Trump repeatedly promoted hydroxychloroquine at press conferences, touting it as a game changer, and even took it himself. The F.D.A. temporarily granted hydroxychloroquine emergency authorization for use in Covid-19 patients which a whistleblower later claimed was the result of political pressure. In the wake of the drugs newfound publicity, demand spiked, resulting in shortages for people who rely on hydroxychloroquine as a treatment for other diseases.

But more detailed studies proved disappointing. A study on monkeys found that hydroxychloroquine didnt prevent the animals from getting infected and didnt clear the virus once they got sick. Randomized clinical trials found that hydroxychloroquine didnt help people with Covid-19 get better or prevent healthy people from contracting the coronavirus. Another randomized clinical trial found that giving hydroxychloroquine to people right after being diagnosed with Covid-19 didnt reduce the severity of their disease. (One large-scale study that concluded the drug was harmful as well was later retracted.) The World Health Organization, the National Institutes of Health and Novartis have since halted trials investigating hydroxychloroquine as a treatment for Covid-19, and the F.D.A. revoked its emergency approval. The F.D.A. now warns that the drug can cause a host of serious side effects to the heart and other organs when used to treat Covid-19.

In July, researchers at Henry Ford hospital in Detroit published a study finding that hydroxychloroquine was associated with a reduction in mortality in Covid-19 patients. President Trump praised the study on Twitter, but experts raised doubts about it. The study was not a randomized controlled trial, in which some people got a placebo instead of hydroxychloroquine. The studys results might not be due to the drug killing the virus. Instead, doctors may have given the drug to people who were less sick, and thus more likely to recover anyway.

Despite negative results, a number of hydroxychloroquine trials have continued, although most are small, testing a few dozen or a few hundred patients. A recent analysis by STAT and Applied XL found more than 180 ongoing clinical trials testing hydroxychloroquine or chloroquine, for treating or preventing Covid-19. Although its clear the drugs are no panacea, its theoretically possible they could provide some benefit in combination with other treatments, or when given in early stages of the disease. Only well-designed trials can determine if thats the case.Updated Aug. 10

Most people who get Covid-19 successfully fight off the virus with a strong immune response. Drugs might help people who cant mount an adequate defense.

TENTATIVE OR MIXED EVIDENCE EVIDENCE IN CELLS AND HUMANS Convalescent plasmaA century ago, doctors filtered plasma from the blood of recovered flu patients. So-called convalescent plasma, rich with antibodies, helped people sick with flu fight their illness. Now researchers are trying out this strategy on Covid-19. In May, the F.D.A. designated convalescent plasma an investigational product. That means that despite not yet being shown as safe and effective, plasma can be used in clinical trials and given to some patients who are seriously ill with Covid-19. Tens of thousands of patients in the U.S. have received plasma through a program launched by the Mayo Clinic and the federal government.

The Trump administration has praised convalescent plasma, despite the lack of evidence yet that it works. The first wave of trials have been small and the results have been mixed. Large randomized clinical trials are underway, but theyve struggled to enroll enough participants, some of whom worry they will receive a placebo instead of the treatment itself.

Experts say that its vital to complete these trials to determine if convalescent plasma is safe and effective. If these trials are successful, it could serve as an important stopgap measure until more potent therapies become widely available.Updated Aug. 10

TENTATIVE OR MIXED EVIDENCE EVIDENCE IN CELLS, ANIMALS AND HUMANSMonoclonal antibodiesConvalescent plasma from people who recover from Covid-19 contains a mix of different antibodies. Some of the molecules can attack the coronavirus, but many are directed at other pathogens. Researchers have sifted through this slurry to find the most potent antibodies against Covid-19. They have then manufactured synthetic copies of these molecules, known as monoclonal antibodies. Researchers have begun investigating them as a treatment for Covid-19, either individually or in cocktails.

Monoclonal antibodies were first developed as a therapy in the 1970s, and since then the F.D.A. has approved them for 79 diseases, ranging from cancer to AIDS. Since the start of the pandemic, researchers have found dozens of monoclonal antibodies that show promise against Covid-19 in preclinical studies on cells and animals. Companies like Eli Lilly and Regeneron recently began clinical trials studying monoclonal antibodies. Several other firms, as well as teams at universities, are slated to enter the race soon as well.Updated Aug. 10

TENTATIVE OR MIXED EVIDENCE EVIDENCE IN CELLS, ANIMALS AND HUMANSInterferonsInterferons are molecules our cells naturally produce in response to viruses. They have profound effects on the immune system, rousing it to attack the invaders, while also reining it in to avoid damaging the bodys own tissues. Injecting synthetic interferons is now a standard treatment for a number of immune disorders. Rebif, for example, is prescribed for multiple sclerosis.

As part of its strategy to attack our bodies, the coronavirus appears to tamp down interferon. That finding has encouraged researchers to see whether a boost of interferon might help people weather Covid-19, particularly early in infection. Early studies, including experiments in cells and mice, have yielded encouraging results that have led to clinical trials.

An open-label study in China suggested that the molecules could help prevent healthy people from getting infected. On July 20, the British pharmaceutical company Synairgen announced that an inhaled form of interferon called SNG001 lowered the risk of severe Covid-19 in infected patients in a small clinical trial. The full data have not yet been released to the public, or published in a scientific journal. On August 6, the National Institute of Allergy and Infectious Diseases launched a Phase III trial on a combination of Rebif and the antiviral remdesivir, with results expected by fall 2020.Updated Aug. 10

The most severe symptoms of Covid-19 are the result of the immune systems overreaction to the virus. Scientists are testing drugs that can rein in its attack.

PROMISING EVIDENCE EVIDENCE IN HUMANS DexamethasoneThis cheap and widely available steroid blunts many types of immune responses. Doctors have long used it to treat allergies, asthma and inflammation. In June, it became the first drug shown to reduce Covid-19 deaths. That study of more than 6,000 people, which in July was published in the New England Journal of Medicine, found that dexamethasone reduced deaths by one-third in patients on ventilators, and by one-fifth in patients on oxygen. It may be less likely to help and may even harm patients who are at an earlier stage of Covid-19 infections, however. In its Covid-19 treatment guidelines, the National Institutes of Health recommends only using dexamethasone in patients with COVID-19 who are on a ventilator or are receiving supplemental oxygen.

TENTATIVE OR MIXED EVIDENCE EVIDENCE IN HUMANS Cytokine InhibitorsThe body produces signaling molecules called cytokines to fight off diseases. But manufactured in excess, cytokines can trigger the immune system to wildly overreact to infections, in a process sometimes called a cytokine storm. Researchers have created a number of drugs to halt cytokine storms, and they have proven effective against arthritis and other inflammatory disorders. Some turn off the supply of molecules that launch the production of the cytokines themselves. Others block the receptors on immune cells to which cytokines would normally bind. A few block the cellular messages they send. Depending on how the drugs are formulated, they can block one cytokine at a time, or muffle signals from several at once.

Against the coronavirus, several of these drugs have offered modest help in some trials, but faltered in others. Drug companies Regeneron and Roche drug both recently announced that two drugs called sarilumab and tocilizumab, which both target the cytokine IL-6, did not appear to benefit patients in Phase 3 clinical trials. Many other trials remain underway, several of which combine cytokine inhibitors with other treatments.Updated Aug. 10

TENTATIVE OR MIXED EVIDENCE EVIDENCE IN HUMANS EMERGENCY USE AUTHORIZATIONBlood filtration systemsThe F.D.A. has granted emergency use authorization to several devices that filter cytokines from the blood in an attempt to cool cytokine storms. One machine, called Cytosorb, can reportedly purify a patients entire blood supply about 70 times in a 24-hour period. A small study in March suggested that Cytosorb had helped dozens of severely ill Covid-19 patients in Europe and China, but it was not a randomized clinical trial that could conclusively demonstrate it was effective. A number of studies on blood filtration systems are underway, but experts caution that these devices carry some risks. For example, such filters could remove beneficial components of blood as well, such as vitamins or medications.Updated Aug. 10

TENTATIVE OR MIXED EVIDENCE EVIDENCE IN HUMANS Stem cellsCertain kinds of stem cells can secrete anti-inflammatory molecules. Over the years, researchers have tried to use them as a treatment for cytokine storms, and now dozens of clinical trials are under way to see if they can help patients with Covid-19. But these stem cell treatments havent worked well in the past, and its not clear yet if theyll work against the coronavirus.

Doctors and nurses often administer other supportive treatments to help patients with Covid-19.

WIDELY USEDProne positioningThe simple act of flipping Covid-19 patients onto their bellies opens up the lungs. The maneuver has become commonplace in hospitals around the world since the start of the pandemic. It might help some individuals avoid the need for ventilators entirely. The treatments benefits continue to be tested in a range of clinical trials.

WIDELY USEDEMERGENCY USE AUTHORIZATIONVentilators and other respiratory support devicesDevices that help people breathe are an essential tool in the fight against deadly respiratory illnesses. Some patients do well if they get an extra supply of oxygen through the nose or via a mask connected to an oxygen machine. Patients in severe respiratory distress may need to have a ventilator breathe for them until their lungs heal. Doctors are divided about how long to treat patients with noninvasive oxygen before deciding whether or not they need a ventilator. Not all Covid-19 patients who go on ventilators survive, but the devices are thought to be lifesaving in many cases.

TENTATIVE OR MIXED EVIDENCE EVIDENCE IN HUMANS AnticoagulantsThe coronavirus can invade cells in the lining of blood vessels, leading to tiny clots that can cause strokes and other serious harm. Anticoagulants are commonly used for other conditions, such as heart disease, to slow the formation of clots, and doctors sometimes use them on patients with Covid-19 who have clots. Many clinical trials teasing out this relationship are now underway. Some of these trials are looking at whether giving anticoagulants before any sign of clotting is beneficial.

False claims about Covid-19 cures abound. The F.D.A. maintains a list of more than 80 fraudulent Covid-19 products, and the W.H.O. debunks many myths about the disease.

WARNING: DO NOT DO THISDrinking or injecting bleach and disinfectantsIn April, President Trump suggested that disinfectants such as alcohol or bleach might be effective against the coronavirus if directly injected into the body. His comments were immediately refuted by health professionals and researchers around the world as well as the makers of Lysol and Clorox. Ingesting disinfectant would not only be ineffective against the virus, but also hazardous possibly even deadly. In July, Federal prosecutors charged four Florida men with marketing bleach as a cure for COVID-19.

WARNING: NO EVIDENCEUV lightPresident Trump also speculated about hitting the body with ultraviolet or just very powerful light. Researchers have used UV light to sterilize surfaces, including killing viruses, in carefully managed laboratories. But UV light would not be able to purge the virus from within a sick persons body. This kind of radiation can also damage the skin. Most skin cancers are a result of exposure to the UV rays naturally present in sunlight.

WARNING: NO EVIDENCESilverThe F.D.A. has threatened legal action against a host of people claiming silver-based products are safe and effective against Covid-19 including televangelist Jim Bakker and InfoWars host Alex Jones. Several metals do have natural antimicrobial properties. But products made from them have not been shown to prevent or treat the coronavirus.

Note: After additional discussions with experts we have adjusted several labels on the tracker. The Strong evidence label has been removed until further research identifies treatments that consistently benefit groups of patients infected by the coronavirus. In its place, Promising evidence will be used for drugs such as remdesivir and dexamethasone that have shown promise in at least one randomized controlled trial, and Widely used for treatments such as proning and ventilators that are often used with severely ill patients, including those with Covid-19. And we may reintroduce the Ineffective label when ongoing clinical trials repeatedly end with disappointing results.

Sources: National Library of Medicine; National Institutes of Health; William Amarquaye, University of South Florida; Paul Bieniasz, Rockefeller University; Jeremy Faust, Brigham & Womens Hospital; Matt Frieman, University of Maryland School of Medicine; Noah Haber, Stanford University; Swapnil Hiremath, University of Ottawa; Akiko Iwaskai, Yale University; Paul Knoepfler, University of California, Davis; Elena Massarotti, Brigham and Womens Hospital; John Moore and Douglas Nixon, Weill Cornell Medical College; Erica Ollman Saphire, La Jolla Institute for Immunology; Regina Rabinovich, Harvard T.H. Chan School of Public Health; Ilan Schwartz, University of Alberta; Phyllis Tien, University of California, San Francisco.

Follow this link:
Coronavirus Drug and Treatment Tracker - The New York Times

Sick of sourdough bread yet? 5 sourdough dishes beyond the basic loaf: empanadas, waffles, popovers, crepes and crackers – San Antonio Express-News

At the onset of the COVID-19 outbreak, the coronavirus wasnt the only bug America became obsessed with. Practically overnight, seemingly every American now flush with time and boredom started to bake sourdough bread.

Flour and yeast disappeared from grocery store shelves. Boundless boules and batards both popular sourdough loaf shapes spread faster than any virus on countless social media threads. Home baked bread was back, and in a big way.

But like any new lifestyle we love to crow about on social media a new fitness routine, the Whole30 challenge, selling essential oils beginners enthusiasm sometimes outstripped the reality of the commitment that keeping sourdough starter alive demands. Many ghosted on their bready crush, seeking fulfillment elsewhere. But for a lucky masochistic few, a lifelong passion ignited.

I killed my starter twice. It really was like feeding a pet, said Katie Kinder DeBauche, the vice president of development at the Witte Museum. She was working from home and had played with sourdough a few times before.

She named her starter Dolores after the Westworld character Dolores Abernathy, whos known for regenerating multiple times after death. Kinder DeBauche, made sure to keep a portion of Dolores as a backup in the fridge just in case. Id forget about her on the counter. Shes been reincarnated twice.

On ExpressNews.com: Sourdough is back, connecting new generations of bakers with starters decades old

San Antonio chef Dave Terrazas found himself laid off from his job with Mercy Chefs and getting familiar with yeast, flour and water at the onset of the coronavirus outbreak as well. From March into the early summer, Terrazas could be found in his kitchen stirring, kneading and baking up loaves of sourdough bread. Hed had an on-again-off-again relationship with sourdough before the pandemic.

But his efforts went onto a back burner once the heat cranked up. His starter, which never received a name, has passed on to the great, bubbly beyond.

Once the garden season went into full swing around May, that was just so time consuming, Terrazas said. He helped plant about a half-dozen gardens for himself and fellow culinary professionals. The camaraderie and fun of building gardens kind of took over.

For both, the sourdough adventure led to learning a lot about bread and what else sourdough starter can become.

The sourdough starter feeding process involves generating a considerable quantity of what bakers often call discard, or a portion of starter thats no longer needed after a fresh feeding. That discard is loaded with a wide range of flavorful and aromatic bacteria and yeast. Many bakers throw it out, but that discard can be used to make countless other things.

Kinder DeBauche said she hated that waste, so she looked for recipes that went beyond the basic loaf.

On ExpressNews.com: No-knead bread still the king of viral recipes

The best and worst thing that happened to me during the quarantine is sourdough waffles. Its not so much the waffle thats bad for you, but what you put on them, she said with a laugh.

Terrazas also found the sourdough discard to be the biggest revelation of his quarantine baking efforts.

Waste not, want not, Terrazas said. It would be a shame wasting a cup or 2 every day. It has all those flavors in it. That flavorful waste product became waffles, empanadas, pasta and more in his kitchen.

Pasta, Terrazas said, was particularly interesting. Typically, pasta doesnt contain any yeast or other leavening agents. The starter, he said, gave his noodles a bounce similar to traditional ramen noodles, which are cooked in water containing one of several kinds of alkaline salt to achieve their unique texture.

On ExpressNews.com: 4 oven-free icebox pies: Margarita, chocolate, lemon and dulce de leche

Playing with sourdough gave both Terrazas and Kinder DeBauche other creative and professional outlets, as well.

For Kinder DeBauche, baking became a way to connect with her family. Her great grandparents were immigrant bakers from Poland who settled in New Jersey. Shes documented the process of teaching herself to bake on her blog at katiesmidnightbaker.com. Shes also turned her baking exploits into a side hustle selling batches of Parker House rolls made from her familys secret recipe.

Terrazas saw sourdough as a perfect educational vehicle. In the coming weeks he plans to launch an online program called Foodie Classroom. The website, foodieclassroom.com, will go live in coming weeks.

Foodie Classroom will take the state standards for all the STEM classes and use food as a contextual element. Algebra can be used to upscale a recipe. Geometry can be used to calculate the area of a pizza. Terrazas explained. Ill be filming videos in farms, gardens, parks and kitchens around the city.

And sourdough will play a roll in that education.

Part of the reason for the whole sourdough thing was Foodie Classroom, he said. Ninth grade biology is all about the life cycle of cells.

If, like Terrazas and Kinder DeBauche, you want options for what to do with the starter discard, were providing you with some sourdough recipes that go beyond the basic loaf.

Recipe: Sourdough Waffles

Recipe: Sourdough Empanadas

Recipe: Sourdough Popovers

Recipe: Sourdough Crepes

Recipe: Sourdough Crackers

Recipe: Sourdough Starter

Paul Stephen is a food and drink reporter and restaurant critic in the San Antonio and Bexar County area. To read more from Paul, become a subscriber. pstephen@express-news.net | Twitter: @pjbites | Instagram: @pjstephen

Continued here:
Sick of sourdough bread yet? 5 sourdough dishes beyond the basic loaf: empanadas, waffles, popovers, crepes and crackers - San Antonio Express-News

Veterinary Scholars Symposium Showcases Veterinary Talent And Highlights Need For Continued Innovation In Advancing Animal And Human Health -…

DULUTH, Ga., Aug. 6, 2020 /PRNewswire/ --More than 500 veterinary students from across the U.S., as well as animal health researchers and leaders from three dozen top veterinary schools, convened virtually this week for the Veterinary Summer Scholars Symposium and presentation of the annual Boehringer Ingelheim Research Awards for Graduate Veterinarians and Veterinary Students.

This annual scientific colloquium normally conducted in person -- showcases research by veterinary students completing summer research internships. It provides an opportunity for students in the Boehringer Ingelheim Veterinary Scholars Program to present and discuss research findings. Veterinary Scholars also have the opportunity to network with each other and with mentors from academia, industry and government.

The Boehringer Ingelheim Veterinary Scholars Program was established more than 30 years ago to introduce first- and second-year veterinary medical students to biomedical research. Nearly 4,000 students have received stipends from Boehringer Ingelheim to conduct research since the program started. More information is available at http://veterinaryscholars.boehringer-ingelheim.com/.

At each participating school, Boehringer Ingelheim Veterinary Scholars are assigned a mentor and laboratory. Each scholar conducts a hypothesis-driven research project. The research project is typically conducted over a 10-12 week period during the summer, with students presenting their work at the conclusion. This year, the 35 participating schools quickly deployed alternative plans to comply with COVID-19 safety measures. Some offered lab-based projects to students in a way that provided social distancing and related protections. Others refocused students' research work on projects involving data analysis, which could be conducted offsite.

"We hope that some good can come from the many lessons we have learned during this year's pandemic, such that we can better detect and treat -- or even prevent -- the next pandemic or major threat to human and animal health," said Caroline Belmont, head of U.S. Animal Health Innovation for Boehringer Ingelheim. "Recent events have highlighted how important both innovation and collaboration are in addressing unmet needs in animal and human health. We look forward to the many future contributions today's veterinary students and researchers will make in advancing these efforts."

Students from the more than three dozen veterinary schools participating in the Veterinary Scholars Program are eligible to apply for two annual awards: The Boehringer Ingelheim Veterinary Graduate Award and the Veterinary Research Scholar Award. Winning students receive monetary prizes and a stipend to attend the annual Veterinary Scholars Symposium to accept their awards and present their research.

The 2020 Boehringer Ingelheim Veterinary Graduate Award was presented at the virtual Veterinary Scholars Symposium to Dr. Sara Hamman Osum, a graduate student completing her Ph.D. in the Comparative and Molecular Biosciences Graduate Program at the University of Minnesota's College of Veterinary Medicine.

Dr. Osum's Ph.D. research has focused on developing and characterizing the first porcine model of Neurofibromatosis type 1 (NF1), a devastating neurologic disease for which there is no cure. Before joining the DVM/PhD program at the University of Minnesota, she spent four years as a research associate, studying tolerance and autoimmunity models and fostering her interest in advancing animal welfare through the development of improved animal models for preclinical research. Dr. Osum received her Doctor of Veterinary Medicine from the University of Minnesota in 2016, and her Bachelor of Science in Biology from the University of California in Santa Cruz, Calif., in 2008.

The Boehringer Ingelheim Veterinary Graduate Award promotes research in veterinary biosciences. It recognizes graduate veterinarians who have completed or will soon complete a Ph.D. program or are in their final years of residency training in veterinary pathology, medicine, surgery, radiology/ imaging, or laboratory animal medicine. Recipients receive an honorarium and are invited to present their research at the annual Veterinary Scholars Symposium.

The recipient of the 2020 Boehringer Ingelheim Veterinary Research Scholar Awardis Megan Fahey, a DVM and Ph.D. degree student at Cornell University's College of Veterinary Medicine. Fahey is committed to a career as a veterinary clinician scientist, and her research interests have evolved to focus on zoonotic disease, virology, and immunology. Her work in the Boehringer Ingelheim Veterinary Scholars Program has involved exploration of the use of mesenchymal stem cells to prevent or reduce degeneration in intervertebral disc disease.

Caroline Schlaeppi Fisher, from North Carolina State University's College of Veterinary Medicine, received an honorable mention, 2020Boehringer Ingelheim Veterinary Research Scholar. That distinction recognizes herwork evaluating the effectiveness of reuse and sterilization of certain devices used in veterinary surgery, work intended to help shape evidence-based guidelines for the reuse of these devices.

Boehringer Ingelheim Animal Health The lives of animals and humans are interconnected in deep and complex ways. We know that when animals are healthy, humans are healthier too. Across the globe, our 10,000 employees are dedicated to delivering value through innovation, thus enhancing the well-being of both.

Respect for animals, humans and the environment is at the heart of what we do. We develop solutions and provide services to protect animals from disease and pain. We support our customers in taking care of the health of their animals and protect our communities against life- and society- threatening diseases.

Boehringer Ingelheim Animal Health is the second largest animal health business in the world, with net sales of $4.5 billion (4 billion euros) in 2019 and presence in more than 150 countries.

Boehringer Ingelheim Animal Health has a significant presence in the United States, with more than 3,100 employees in places that include Georgia, Missouri, Iowa, Minnesota, New Jersey and Puerto Rico. To learn more, visit http://www.boehringer-ingelheim.us, http://www.facebook.com/BoehringerAHUS or http://www.twitter.com/Boehringer_AH.

Boehringer Ingelheim Making new and better medicines for humans and animals is at the heart of what we do. Our mission is to create breakthrough therapies that change lives. Since its founding in 1885, Boehringer Ingelheim has been independent and family-owned. We have the freedom to pursue our long-term vision, looking ahead to identify the health challenges of the future and targeting those areas of need where we can do the most good.

As a world-leading, research-driven pharmaceutical company, more than 51,000 employees create value through innovation daily for our three business areas: Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing.

In 2019, Boehringer Ingelheim achieved net sales of $21.3 billion (19 billion euros). Our significant investment of over $3.9 billion (3.5 billion euros) in R&D drives innovation, enabling the next generation of medicines that save lives and improve quality of life.

We realize more scientific opportunities by embracing the power of partnership and diversity of experts across the life-science community. By working together, we accelerate the delivery of the next medical breakthrough that will transform the lives of patients now, and in generations to come.

More information about Boehringer Ingelheim can be found at http://www.boehringer-ingelheim.com or in our annual report: http://annualreport.boehringer-ingelheim.com.

SOURCE Boehringer Ingelheim Animal Health USA Inc.

http://www.boehringer-ingelheim.us

Read more:
Veterinary Scholars Symposium Showcases Veterinary Talent And Highlights Need For Continued Innovation In Advancing Animal And Human Health -...

Biotechnology Could Change the Cattle Industry. Will it Succeed? – Undark Magazine

When Ralph Fisher, a Texas cattle rancher, set eyes on one of the worlds first cloned calves in August 1999, he didnt care what the scientists said: He knew it was his old Brahman bull, Chance, born again. About a year earlier, veterinarians at Texas A&M extracted DNA from one of Chances moles and used the sample to create a genetic double. Chance didnt live to meet his second self, but when the calf was born, Fisher christened him Second Chance, convinced he was the same animal.

Scientists cautioned Fisher that clones are more like twins than carbon copies: The two may act or even look different from one another. But as far as Fisher was concerned, Second Chance was Chance. Not only did they look identical from a certain distance, they behaved the same way as well. They ate with the same odd mannerisms; laid in the same spot in the yard. But in 2003, Second Chance attacked Fisher and tried to gore him with his horns. About 18 months later, the bull tossed Fisher into the air like an inconvenience and rammed him into the fence. Despite 80 stitches and a torn scrotum, Fisher resisted the idea that Second Chance was unlike his tame namesake, telling the radio program This American Life that I forgive him, you know?

In the two decades since Second Chance marked a genetic engineering milestone, cattle have secured a place on the front lines of biotechnology research. Today, scientists around the world are using cutting-edge technologies, from subcutaneous biosensors to specialized food supplements, in an effort to improve safety and efficiency within the $385 billion global cattle meat industry. Beyond boosting profits, their efforts are driven by an imminent climate crisis, in which cattle play a significant role, and growing concern for livestock welfare among consumers.

Gene editing stands out as the most revolutionary of these technologies. Although gene-edited cattle have yet to be granted approval for human consumption, researchers say tools like Crispr-Cas9 could let them improve on conventional breeding practices and create cows that are healthier, meatier, and less detrimental to the environment. Cows are also being given genes from the human immune system to create antibodies in the fight against Covid-19. (The genes of non-bovine livestock such as pigs and goats, meanwhile, have been hacked to grow transplantable human organs and produce cancer drugs in their milk.)

But some experts worry biotech cattle may never make it out of the barn. For one thing, theres the optics issue: Gene editing tends to grab headlines for its role in controversial research and biotech blunders. Crispr-Cas9 is often celebrated for its potential to alter the blueprint of life, but that enormous promise can become a liability in the hands of rogue and unscrupulous researchers, tempting regulatory agencies to toughen restrictions on the technologys use. And its unclear how eager the public will be to buy beef from gene-edited animals. So the question isnt just if the technology will work in developing supercharged cattle, but whether consumers and regulators will support it.

Cattle are catalysts for climate change. Livestock account for an estimated 14.5 percent of greenhouse gas emissions from human activities, of which cattle are responsible for about two thirds, according to the United Nations Food and Agriculture Organization (FAO). One simple way to address the issue is to eat less meat. But meat consumption is expected to increase along with global population and average income. A 2012 report by the FAO projected that meat production will increase by 76 percent by 2050, as beef consumption increases by 1.2 percent annually. And the United States is projected to set a record for beef production in 2021, according to the Department of Agriculture.

For Alison Van Eenennaam, an animal geneticist at the University of California, Davis, part of the answer is creating more efficient cattle that rely on fewer resources. According to Van Eenennaam, the number of dairy cows in the United States decreased from around 25 million in the 1940s to around 9 million in 2007, while milk production has increased by nearly 60 percent. Van Eenennaam credits this boost in productivity to conventional selective breeding.

You dont need to be a rocket scientist or even a mathematician to figure out that the environmental footprint or the greenhouse gases associated with a glass of milk today is about one-third of that associated with a glass of milk in the 1940s, she says. Anything you can do to accelerate the rate of conventional breeding is going to reduce the environmental footprint of a glass of milk or a pound of meat.

Modern gene-editing tools may fuel that acceleration. By making precise cuts to DNA, geneticists insert or remove naturally occurring genes associated with specific traits. Some experts insist that gene editing has the potential to spark a new food revolution.

The question isnt just if the technology will work in developing supercharged cattle, but whether consumers and regulators will support it.

Jon Oatley, a reproductive biologist at Washington State University, wants to use Crispr-Cas9 to fine tune the genetic code of rugged, disease-resistant, and heat-tolerant bulls that have been bred to thrive on the open range. By disabling a gene called NANOS2, he says he aims to eliminate the capacity for a bull to make his own sperm, turning the recipient into a surrogate for sperm-producing stem cells from more productive prized stock. These surrogate sires, equipped with sperm from prize bulls, would then be released into range herds that are often genetically isolated and difficult to access, and the premium genes would then be transmitted to their offspring.

Furthermore, surrogate sires would enable ranchers to introduce desired traits without having to wrangle their herd into one place for artificial insemination, says Oatley. He envisions the gene-edited bulls serving herds in tropical regions like Brazil, the worlds largest beef exporter and home to around 200 million of the approximately 1.5 billion head of cattle on Earth.

Brazils herds are dominated by Nelore, a hardy breed that lacks the carcass and meat quality of breeds like Angus but can withstand high heat and humidity. Put an Angus bull on a tropical pasture and hes probably going to last maybe a month before he succumbs to the environment, says Oatley, while a Nelore bull carrying Angus sperm would have no problem with the climate.

The goal, according to Oatley, is to introduce genes from beefier bulls into these less efficient herds, increasing their productivity and decreasing their overall impact on the environment. We have shrinking resources, he says, and need new, innovative strategies for making those limited resources last.

Oatley has demonstrated his technique in mice but faces challenges with livestock. For starters, disabling NANOS2 does not definitively prevent the surrogate bull from producing some of its own sperm. And while Oatley has shown he can transplant sperm-producing cells into surrogate livestock, researchers have not yet published evidence showing that the surrogates produce enough quality sperm to support natural fertilization. How many cells will you need to make this bull actually fertile? asks Ina Dobrinski, a reproductive biologist at the University of Calgary who helped pioneer germ cell transplantation in large animals.

But Oatleys greatest challenge may be one shared with others in the bioengineered cattle industry: overcoming regulatory restrictions and societal suspicion. Surrogate sires would be classified as gene-edited animals by the Food and Drug Administration, meaning theyd face a rigorous approval process before their offspring could be sold for human consumption. But Oatley maintains that if his method is successful, the sperm itself would not be gene-edited, nor would the resulting offspring. The only gene-edited specimens would be the surrogate sires, which act like vessels in which the elite sperm travel.

Even so, says Dobrinski, Thats a very detailed difference and Im not sure how that will work with regulatory and consumer acceptance.

In fact, American attitudes towards gene editing have been generally positive when the modification is in the interest of animal welfare. Many dairy farmers prefer hornless cows horns can inflict damage when wielded by 1,500-pound animals so they often burn them off in a painful process using corrosive chemicals and scalding irons. In a study published last year in the journal PLOS One, researchers found that most Americans are willing to consume food products from cows genetically modified to be hornless.

Still, experts say several high-profile gene-editing failures in livestock and humans in recent years may lead consumers to consider new biotechnologies to be dangerous and unwieldy.

In 2014, a Minnesota startup called Recombinetics, a company with which Van Eenennaams lab has collaborated, created a pair of cross-bred Holstein bulls using the gene-editing tool TALENs, a precursor to Crispr-Cas9, making cuts to the bovine DNA and altering the genes to prevent the bulls from growing horns. Holstein cattle, which almost always carry horned genes, are highly productive dairy cows, so using conventional breeding to introduce hornless genes from less productive breeds can compromise the Holsteins productivity. Gene editing offered a chance to introduce only the genes Recombinetics wanted. Their hope was to use this experiment to prove that milk from the bulls female progeny was nutritionally equivalent to milk from non-edited stock. Such results could inform future efforts to make Holsteins hornless but no less productive.

The experiment seemed to work. In 2015, Buri and Spotigy were born. Over the next few years, the breakthrough received widespread media coverage, and when Buris hornless descendant graced the cover of Wired magazine in April 2019, it did so as the ostensible face of the livestock industrys future.

But early last year, a bioinformatician at the FDA ran a test on Buris genome and discovered an unexpected sliver of genetic code that didnt belong. Traces of bacterial DNA called a plasmid, which Recombinetics used to edit the bulls genome, had stayed behind in the editing process, carrying genes linked to antibiotic resistance in bacteria. After the agency published its findings, the media reaction was swift and fierce: FDA finds a surprise in gene-edited cattle: antibiotic-resistant, non-bovine DNA, read one headline. Part cow, part bacterium? read another.

Recombinetics has since insisted that the leftover plasmid DNA was likely harmless and stressed that this sort of genetic slipup is not uncommon.

Is there any risk with the plasmid? I would say theres none, says Tad Sonstegard, president and CEO of Acceligen, a Recombinetics subsidiary. We eat plasmids all the time, and were filled with microorganisms in our body that have plasmids. In hindsight, Sonstegard says his teams only mistake was not properly screening for the plasmid to begin with.

While the presence of antibiotic-resistant plasmid genes in beef probably does not pose a direct threat to consumers, according to Jennifer Kuzma, a professor of science and technology policy and co-director of the Genetic Engineering and Society Center at North Carolina State University, it does raise the possible risk of introducing antibiotic-resistant genes into the microflora of peoples digestive systems. Although unlikely, organisms in the gut could integrate those genes into their own DNA and, as a result, proliferate antibiotic resistance, making it more difficult to fight off bacterial diseases.

The lesson that I think is learned there is that science is never 100 percent certain, and that when youre doing a risk assessment, having some humility in your technology product is important, because you never know what youre going to discover further down the road, she says. In the case of Recombinetics. I dont think there was any ill intent on the part of the researchers, but sometimes being very optimistic about your technology and enthusiastic about it causes you to have blinders on when it comes to risk assessment.

The FDA eventually clarified its results, insisting that the study was meant only to publicize the presence of the plasmid, not to suggest the bacterial DNA was necessarily dangerous. Nonetheless, the damage was done. As a result of the blunder,a plan was quashed forRecombinetics to raise an experimental herd in Brazil.

Sometimes being very optimistic about your technology and enthusiastic about it causes you to have blinders on when it comes to risk assessment.

Backlash to the FDA study exposed a fundamental disagreement between the agency and livestock biotechnologists. Scientists like Van Eenennaam, who in 2017 received a $500,000 grant from the Department of Agriculture to study Buris progeny, disagree with the FDAs strict regulatory approach to gene-edited animals. Typical GMOs are transgenic, meaning they have genes from multiple different species, but modern gene-editing techniques allow scientists to stay roughly within the confines of conventional breeding, adding and removing traits that naturally occur within the species. That said, gene editing is not yet free from errors and sometimes intended changes result in unintended alterations, notes Heather Lombardi, division director of animal bioengineering and cellular therapies at the FDAs Center for Veterinary Medicine. For that reason, the FDA remains cautious.

Theres a lot out there that I think is still unknown in terms of unintended consequences associated with using genome-editing technology, says Lombardi. Were just trying to get an understanding of what the potential impact is, if any, on safety.

Bhanu Telugu, an animal scientist at the University of Maryland and president and chief science officer at the agriculture technology startup RenOVAte Biosciences, worries that biotech companies will migrate their experiments to countries with looser regulatory environments. Perhaps more pressingly, he says strict regulation requiring long and expensive approval processes may incentivize these companies to work only on traits that are most profitable, rather than those that may have the greatest benefit for livestock and society, such as animal well-being and the environment.

What company would be willing to spend $20 million on potentially alleviating heat stress at this point? he asks.

On a windy winter afternoon, Raluca Mateescu leaned against a fence post at the University of Floridas Beef Teaching Unit while a Brahman heifer sniffed inquisitively at the air and reached out its tongue in search of unseen food. Since 2017, Mateescu, an animal geneticist at the university, has been part of a team studying heat and humidity tolerance in breeds like Brahman and Brangus (a mix between Brahman and Angus cattle). Her aim is to identify the genetic markers that contribute to a breeds climate resilience, markers that might lead to more precise breeding and gene-editing practices.

In the South, Mateescu says, heat and humidity are a major problem. That poses a stress to the animals because theyre selected for intense production to produce milk or grow fast and produce a lot of muscle and fat.

Like Nelore cattle in South America, Brahman are well-suited for tropical and subtropical climates, but their high tolerance for heat and humidity comes at the cost of lower meat quality than other breeds. Mateescu and her team have examined skin biopsies and found that relatively large sweat glands allow Brahman to better regulate their internal body temperature. With funding from the USDAs National Institute of Food and Agriculture, the researchers now plan to identify specific genetic markers that correlate with tolerance to tropical conditions.

If were selecting for animals that produce more without having a way to cool off, were going to run into trouble, she says.

A Brahman cow at the University of Floridas Beef Teaching Unit. Visual: Dyllan Furness

There are other avenues in biotechnology beyond gene editing that may help reduce the cattle industrys footprint. Although still early in their development, lab-cultured meats may someday undermine todays beef producers by offering consumers an affordable alternative to the conventionally grown product, without the animal welfare and environmental concerns that arise from eating beef harvested from a carcass.

Other biotech techniques hope to improve the beef industry without displacing it. In Switzerland, scientists at a startup called Mootral are experimenting with a garlic-based food supplement designed to alter the bovine digestive makeup to reduce the amount of methane they emit. Studies have shown the product to reduce methane emissions by about 20 percent in meat cattle, according to The New York Times.

In order to adhere to the Paris climate agreement, Mootrals owner, Thomas Hafner, believes demand will grow as governments require methane reductions from their livestock producers. We are working from the assumption that down the line every cow will be regulated to be on a methane reducer, he told The New York Times.

Meanwhile, a farm science research institute in New Zealand, AgResearch, hopes to target methane production at its source by eliminating methanogens, the microbes thought to be responsible for producing the greenhouse gas in ruminants. The AgResearch team is attempting to develop a vaccine to alter the cattle guts microbial composition, according to the BBC.

Genomic testing may also allow cattle producers to see what genes calves carry before theyre born, according to Mateescu, enabling producers to make smarter breeding decisions and select for the most desirable traits, whether it be heat tolerance, disease resistance, or carcass weight.

Despite all these efforts, questions remain as to whether biotech can ever dramatically reduce the industrys emissions or afford humane treatment to captive animals in resource-intensive operations. To many of the industrys critics, including environmental and animal rights activists, the very nature of the practice of rearing livestock for human consumption erodes the noble goal of sustainable food production. Rather than revamp the industry, these critics suggest alternatives such as meat-free diets to fulfill our need for protein. Indeed, data suggests many young consumers are already incorporating plant-based meats into their meals.

Ultimately, though, climate change may be the most pressing issue facing the cattle industry, according to Telugu of the University of Maryland, which received a grant from the Bill and Melinda Gates Foundation to improve productivity and adaptability in African cattle. We cannot breed our way out of this, he says.

Dyllan Furness is a Florida-based science and technology journalist. His work has appeared in Quartz, OneZero, and PBS, among other outlets.

See the original post:
Biotechnology Could Change the Cattle Industry. Will it Succeed? - Undark Magazine

Back to Top